COMP <GO>
STIM vs KRMD // ENTERPRISE SCALE & MARKET CAP
Neuronetics Inc. (NASDAQ) VS. KORU Medical Systems Inc. (NASDAQ) • 15-METRIC TALLY: STIM 3
— KRMD 7
▲ ENTERPRISE SCALE & MARKET CAP LEADER: STIM
LAST: $2.38 (+5.31%) • MKT CAP: $181.3M
market-cap
$181.3M
LAST: $3.23 (+0.31%) • MKT CAP: $149.1M
market-cap
$149.1M
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (STIM VS. KRMD)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | STIM | KRMD | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 48.50% | 62.30% | -13.80 | KRMD | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -28.70% | -6.30 | KRMD | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -11.25% | 0.31% | -11.56 | KRMD | /fcf-yield <GO> |
| Operating Margin | -21.10% | -7.20% | -13.90 | KRMD | /operating-margins <GO> |
| Net Profit Margin | -26.10% | -6.40% | -19.70 | KRMD | /net-margins <GO> |
| Revenue Growth (YoY) | 99.20% | 22.20% | +77.00 | STIM | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.20 | 8.05 | -7.85 | KRMD | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 7/9 | -2.00 | KRMD | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 55.9 | 55.8 | +0.10 | STIM | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap ACTIVE | $181.3M | $149.1M | $32.2M | STIM | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | STIM REV | KRMD REV | STIM GROSS % | KRMD GROSS % | STIM FCF | KRMD FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $149.2M | $41.1M | 48.5% | 62.3% | -$20.4M | $462.4K |
| FY 2024 | $74.9M | $33.6M | 72.3% | 63.4% | -$31.0M | -$319.7K |
| FY 2023 | $71.3M | $28.5M | — | — | -$32.0M | -$4.9M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
STIM // BETA —
KRMD // BETA —